Sponsor

Clinical trials sponsored by Kailera

Active studies whose public registry record names Kailera as lead sponsor.

6active studies

4recruiting now

8countries represented

167largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Obesity With Diabetes, Overweight With DiabetesCondition

Ribupatide, PlaceboTreatment

Argentina, Australia167 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284901See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Obesity, OverweightCondition

Ribupatide, PlaceboTreatment

Argentina, Australia104 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284875See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, SemaglutideTreatment

Australia, Bulgaria59 locations

KaileraSponsor

Updated 2026-09-01 · NCT07284979See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Obesity, OverweightCondition

KAI-7535, PlaceboTreatment

Australia, United States36 locations

KaileraSponsor

Updated 2026-07-28 · NCT07497880See eligibility →

Opening soonPhase 1

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

End Stage Renal Disease, Renal ImpairmentCondition

RibupatideTreatment

United States1 locations

KaileraSponsor

Updated 2026-09-03 · NCT07793929See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, PlaceboTreatment

United States35 locations

KaileraSponsor

Updated 2026-07-15 · NCT07458269See eligibility →

Related sponsors

Novo Nordisk A/S71 Eli Lilly and Company67 University of Colorado, Denver36 Cairo University31 Mayo Clinic29 Norwegian University of Science and Technology25

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.